L. Sherman

发表

Improved survival with MEK inhibition in BRAF-mutated melanoma.

J. Utikal, D. Schadendorf, J. Becker, 2012, The New England journal of medicine.

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.

D. Schadendorf, R. Dummer, M. Casey, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of safety and drug-induced tumor necrosis with sunitinib in patients (pts) with unresectable hepatocellular carcinoma (HCC)

E. Raymond, J. Douillard, Jun Suk Kim, 2007 .

Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers

B. Houk, S. Misbah, J. Smeraglia, 2005 .

Analysis of circulating biomarkers of sunitinib malate in patients with unresectable neuroendocrine tumors (NET): VEGF, IL-8, and soluble VEGF receptors 2 and 3.

L. Tye, H. Lenz, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAFV600/k mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012 .

METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM).

J. Utikal, D. Schadendorf, K. Flaherty, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.

S. Verstovsek, A. Vannucchi, C. Harrison, 2022, Future oncology.

Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study

Y. Bang, Yoon-Koo Kang, H. Chung, 2007 .

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.

E. Vellenga, D. Steensma, P. Fenaux, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD), Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive

E. Vellenga, D. Steensma, P. Fenaux, 2018, Blood.

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

D. Niederwieser, R. Hoffman, A. Vannucchi, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

E. Vellenga, D. Steensma, P. Fenaux, 2019, HemaSphere.

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Dirk Schadendorf, Peter Mohr, Reinhard Dummer, 2012 .

Imetelstat Is Effective Treatment for Patients with Intermediate-2 or High-Risk Myelofibrosis Who Have Relapsed on or Are Refractory to Janus Kinase Inhibitor Therapy: Results of a Phase 2 Randomized Study of Two Dose Levels

D. Niederwieser, R. Hoffman, A. Reiter, 2018, Blood.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

Keith T Flaherty, Paul S Meltzer, Maria J Merino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

G. Shapiro, A. Zhu, E. Heath, 2010, Clinical Cancer Research.

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

J. Smeraglia, L. Sherman, M. Toh, 2010, Cancer Chemotherapy and Pharmacology.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

G. Shapiro, P. LoRusso, S. Swann, 2013, Investigational New Drugs.

A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors

G. Shapiro, P. LoRusso, S. Swann, 2012, Investigational New Drugs.

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

John Smeraglia, J. Smeraglia, L. Sherman, 2006, Anti-cancer drugs.

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

S. Verstovsek, A. Vannucchi, S. Koschmieder, 2022, Blood.

A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor

S. Verstovsek, R. Mesa, A. Vannucchi, 2020 .

A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects

J. Smeraglia, L. Sherman, M. Garrett, 2007 .

Imerge: A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) That Is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

E. Vellenga, D. Steensma, P. Fenaux, 2019, Blood.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study

P. Fenaux, A. Raza, M. Sekeres, 2022, Blood.

On-Target Activity of Imetelstat Correlates with Clinical Benefits, Including Overall Survival (OS), in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

E. Vellenga, P. Fenaux, S. Thépot, 2021, Blood.

Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.

R. Srinivasan, T. Choueiri, S. Srinivas, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.

W Marston Linehan, W. Linehan, R. Srinivasan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

M. Sekeres, U. Platzbecker, V. Santini, 2023, The Lancet.

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer.

H. Burstein, M. Collier, C. Baum, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.